15
Participants
Start Date
February 22, 2022
Primary Completion Date
June 29, 2023
Study Completion Date
June 29, 2023
Dupilumab
"Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.~Additionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints."
University of Michigan, Ann Arbor
Regeneron Pharmaceuticals
INDUSTRY
University of Michigan
OTHER